Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201110-26 Development research of targeted anti-cancer drugs, UAI-201(Oncology, Chemical) [01.04.2013]

PRINT

Development and Market Objectives

As an inhibitor, UAI-201 can overcome the Paradox effect affecting Vemurafenib, and it does not have any toxicity, as well as showing a superior pharmacokinetics quality and better in vivo vitality compared to Vemurafenib.
 

Unmet Medical Need & Target Patients

Status

Lead Optimization

Intellectual Property

WO/2012/074249

Competitive Advantages

As an inhibitor, UAI-201 can overcome the Paradox effect affecting Vemurafenib, and it does not have any toxicity, as well as showing a superior pharmacokinetics quality and better in vivo vitality compared to Vemurafenib.

Indication

Multiple Melanoma
 

Research Period

Mar.15 , 2012 ~ Nov.15 , 2012
 

Company

UAI Co., Ltd
 

Developmental Stage

Lead Optimization
 

Additional Information

WO/2012/074249
 

Contact Information

Contact
Address Company Name: UAI Co., Ltd
WebSite Homepage: http:// Contact Person: Dr. Choe Nam Song
E-mail: nschoi@youai.co.kr Contact: 031-888-6834

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code